Literature DB >> 11956073

Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells.

Liyan Zhuang1, Jianqing Lin, Michael L Lu, Keith R Solomon, Michael R Freeman.   

Abstract

Although cholesterol accumulation in tumors was first reported in the early20th century, the mechanistic implications of this observation are still obscure. Here we report that caveolin-negative human prostate cancer (LNCaP) cells contain cholesterol-rich lipid rafts that mediate epidermal growth factor (EGF)-induced and constitutive signaling through the Akt1 serine-threonine kinase. EGF receptor and Akt1 phosphorylation were inhibited and autonomous cell survival was reduced when the rafts were disrupted. Reconstitution of the rafts with cholesterol restored EGF receptor-->Akt1 axis signaling and cytoprotection from a phosphoinositide 3-kinase-dependent apoptotic signal. These results suggest that cholesterol present in membrane microdomains is a prominent mediator of survival in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956073

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  122 in total

Review 1.  Integrin signaling and mammary cell function.

Authors:  Franziska Schatzmann; Rebecca Marlow; Charles H Streuli
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

2.  The role of proline in the membrane re-entrant helix of caveolin-1.

Authors:  Satoko Aoki; Annick Thomas; Marc Decaffmeyer; Robert Brasseur; Richard M Epand
Journal:  J Biol Chem       Date:  2010-08-20       Impact factor: 5.157

Review 3.  Caveolae as organizers of pharmacologically relevant signal transduction molecules.

Authors:  Hemal H Patel; Fiona Murray; Paul A Insel
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

Review 4.  Molecular pathways: sterols and receptor signaling in cancer.

Authors:  Linara Gabitova; Andrey Gorin; Igor Astsaturov
Journal:  Clin Cancer Res       Date:  2013-10-24       Impact factor: 12.531

5.  Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

Authors:  Xuan Chen; Yue Liu; Jian Wu; Huarong Huang; Zhiyun Du; Kun Zhang; Daiying Zhou; Kaylyn Hung; Susan Goodin; Xi Zheng
Journal:  Cancer Genomics Proteomics       Date:  2016 Mar-Apr       Impact factor: 4.069

6.  Ezetimibe is an inhibitor of tumor angiogenesis.

Authors:  Keith R Solomon; Kristine Pelton; Kelly Boucher; Jinsoo Joo; Christopher Tully; David Zurakowski; Carl P Schaffner; Jayoung Kim; Michael R Freeman
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

Authors:  Emma H Allott; Lauren E Howard; Matthew R Cooperberg; Christopher J Kane; William J Aronson; Martha K Terris; Christopher L Amling; Stephen J Freedland
Journal:  BJU Int       Date:  2014-05-08       Impact factor: 5.588

8.  Effect of nitric oxide on the anticancer activity of the topoisomerase-active drugs etoposide and adriamycin in human melanoma cells.

Authors:  Birandra K Sinha; Ashutosh Kumar; Suchandra Bhattacharjee; Michael G Espey; Ronald P Mason
Journal:  J Pharmacol Exp Ther       Date:  2013-09-18       Impact factor: 4.030

9.  Transforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts.

Authors:  Adam C Midgley; Mathew Rogers; Maurice B Hallett; Aled Clayton; Timothy Bowen; Aled O Phillips; Robert Steadman
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

Review 10.  The emerging role of obesity, diet and lipid metabolism in prostate cancer.

Authors:  Matteo Ferro; Daniela Terracciano; Carlo Buonerba; Giuseppe Lucarelli; Danilo Bottero; Sisto Perdonà; Riccardo Autorino; Alessandro Serino; Francesco Cantiello; Rocco Damiano; Iulia Andras; Sabino De Placido; Giuseppe Di Lorenzo; Michele Battaglia; Barbara A Jereczek-Fossa; Vincenzo Mirone; Ottavio De Cobelli
Journal:  Future Oncol       Date:  2016-09-14       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.